0001415889-20-000125.txt : 20200117 0001415889-20-000125.hdr.sgml : 20200117 20200117165607 ACCESSION NUMBER: 0001415889-20-000125 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20200117 DATE AS OF CHANGE: 20200117 EFFECTIVENESS DATE: 20200117 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AzurRx BioPharma, Inc. CENTRAL INDEX KEY: 0001604191 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-358472 FILM NUMBER: 20534149 BUSINESS ADDRESS: STREET 1: 760 PARKSIDE AVENUE STREET 2: SUITE 304 CITY: BROOKLYN STATE: NY ZIP: 11226 BUSINESS PHONE: 646-699-7855 MAIL ADDRESS: STREET 1: 760 PARKSIDE AVENUE STREET 2: SUITE 304 CITY: BROOKLYN STATE: NY ZIP: 11226 FORMER COMPANY: FORMER CONFORMED NAME: BioPharma d'Azur, Inc. DATE OF NAME CHANGE: 20140331 D 1 primary_doc.xml X0708 D LIVE 0001604191 AzurRx BioPharma, Inc. 760 Parkside Ave. Suite 304 Brooklyn NY NEW YORK 11226 646-699-7855 DELAWARE None BioPharma d'Azur, Inc. Corporation true Daniel Schneiderman 760 Parkside Ave. Suite 304 Brooklyn NY NEW YORK 11226 Executive Officer Edward Borkowski 760 Parkside Ave. Suite 304 Brooklyn NY NEW YORK 11226 Director Alastair Riddell 760 Parkside Ave. Suite 304 Brooklyn NY NEW YORK 11226 Director James Sapirstein 760 Parkside Ave. Suite 304 Brooklyn NY NEW YORK 11226 Executive Officer Director Charles Casamento 760 Parkside Ave. Suite 304 Brooklyn NY NEW YORK 11226 Director Vern Schramm 760 Parkside Ave. Suite 304 Brooklyn NY NEW YORK 11226 Director James Pennington 760 Parkside Ave. Suite 304 Brooklyn NY NEW YORK 11226 Executive Officer Biotechnology No Revenues 06b false 2019-12-20 false true true false 10000 Alexander Capital, L. P. 40077 None None 17 State Street 5th Floor New York NY NEW YORK 10004 AR ARKANSAS CA CALIFORNIA CO COLORADO CT CONNECTICUT FL FLORIDA GA GEORGIA IL ILLINOIS MD MARYLAND MA MASSACHUSETTS NJ NEW JERSEY NY NEW YORK NC NORTH CAROLINA PA PENNSYLVANIA RI RHODE ISLAND SC SOUTH CAROLINA TX TEXAS WI WISCONSIN 8000000 6904000 1096000 Offering completed on January 9, 2020. false 0 70 553860 0 In addition, Alexander Capital, L.P. received a 1% non-accountable expense allowance from gross proceeds from the Offering, or $61,540, and was issued warrants exercisable for 444,104 shares of common stock, at an exercise price of $1.21 per share. 0 AzurRx BioPharma, Inc. /s/ Daniel Schneiderman Daniel Schneiderman Chief Financial Officer 2020-01-17